Clinical feature

        N

RIZ1 unmethylated

          %

RIZ1 methylated

       %

     P Value

Patients

100

91

91%

9

9%

0.06

Controls

50

50

100%

0

0%

 

Age >45

36

33

91.6%

3

8.4%

0.98

Age <45

64

58

90.6%

6

9.4%

 

Males

65

58

89.2%

7

10.7%

0.63

Female

35

33

94.2%

2

5.8%

 

CP-CML

48

46

95.8%

2

4.2%

 

AP-CML

28

27

96.4%

1

3.6%

0.009

BC-CML

24

18

75%

6

25%

 

b2a2

31

29

93.5%

2

6.5%

 

b3a2

67

60

89.5%

7

10.5%

0.73

A2b2/ A2b3

2

2

100%

0

0%

 

MMR

52

51

98.08%

01

1.92%

0.03

Loss of MR

48

40

83.33%

8

16.77%

 

MHR

50

49

98%

01

2%

0.01

Minor HR

10

07

70%

03

30%

 

Minimal HR

40

35

85%

05

12.50%

 

Imatinib alone

90

84

93.33%

6

6.66%

0.02

Imatinib+Dasatanib

07

06

85.70%

1

14.30%

 

Interferon

03

01

33.33%

2

66.66%

 

Thrombocytopenia

60

54

90%

6

10%

0.9

No Thrombocytopenia

40

37

92.5%

3

7.5%

 

MR:Molecular response, HR: Hematological response
Table 5: Correlation between RIZ-1 promoter methylation and the clinical characteristics of CML patients.